LONDON--(BUSINESS WIRE)--The National Institute for Clinical Excellence (NICE), a UK government-funded, non-departmental public body that aims to establish guidelines for clinical best practice, officially evaluated and recommended Qbtech’s objective ADHD testing technology, QbTest, within the National Institute for Health and Care Excellence Diagnostic Assessment Programme.

伦敦——（商业新闻短讯）——国家临床卓越研究所（NICE）是一家由英国政府资助的非部门公共机构，旨在建立临床最佳实践指南，在国家卫生与保健卓越诊断评估计划内正式评估并推荐了Qbtech的客观ADHD测试技术QbTest。

This milestone positions QbTest as the first and only digital technology to be recommended by NICE for ADHD diagnostic supports, representing a significant breakthrough in how ADHD is assessed across the National Health Service (NHS) and beyond..

这一里程碑将QbTest定位为NICE推荐用于ADHD诊断支持的第一项也是唯一一项数字技术，代表着在国家卫生服务局（NHS）及其他机构如何评估ADHD方面的重大突破。。

QbTest is an FDA-cleared, market-leading computer-based test with motion tracking that objectively measures core ADHD symptoms — inattention, impulsivity, and hyperactivity. The results are analyzed and presented in an easy-to-read visual report comparing them to a normative control group of the same age and sex at birth who do not have ADHD.

QbTest是FDA批准的、市场领先的基于计算机的运动跟踪测试，可客观测量ADHD的核心症状-注意力不集中、冲动和多动。将结果进行分析并以易于阅读的视觉报告形式呈现，将其与出生时相同年龄和性别且没有ADHD的规范对照组进行比较。

By integrating QbTest with standard clinical assessment, clinicians can make faster, more accurate diagnostic decisions – ultimately improving patient outcomes and reducing NHS waiting times..

通过将QbTest与标准临床评估相结合，临床医生可以做出更快，更准确的诊断决策-最终改善患者预后并减少NHS等待时间。。

“From a clinical perspective, QbTest has allowed clinical services to reach a diagnosis of ADHD or other explanations for their symptoms more quickly and with greater confidence. These services are in massive demand from the NHS, so this technology is needed more than ever before,” says Professor Richard Morriss, NIHR ARC East Midlands Mental Health and Well-being Theme Lead and Professor of Psychiatry at the University of Nottingham (NIHR, 2024)..

“从临床角度来看，QbTest使临床服务能够更快、更有信心地诊断出ADHD或对其症状做出其他解释。NHS对这些服务的需求量很大，因此比以往任何时候都更需要这项技术，”NIHR ARC East Midlands Mental Health and Well being主题负责人、诺丁汉大学精神病学教授理查德·莫里斯（Richard Morris）教授表示。。

QbTest’s inclusion in NICE’s Diagnostic Guideline (DG60) highlights its effectiveness in streamlining the ADHD diagnostic process across various clinical settings. As part of an NHS England-funded National Programme (FOCUS ADHD), QbTest has been integrated into 15 Health Innovation Networks (HINs) across England, releasing 95,097 hours of healthcare capacity and saving 1,582 clinical appointments across the NHS.

QbTest被纳入NICE的诊断指南（DG60）中，突显了其在各种临床环境中简化ADHD诊断过程的有效性。作为NHS英格兰资助的国家计划（FOCUS ADHD）的一部分，QbTest已被整合到英格兰的15个健康创新网络（HIN）中，释放了95097小时的医疗保健能力，并节省了整个NHS的1582次临床预约。

(NIHR, 2024) (Network, 2024).

（国家人权研究所，2024年）（网络，2024）。

A landmark RCT study (Hollis, 2018) showed that using QbTest alongside a standard clinical assessment resulted in significantly quicker diagnostic decisions without compromising accuracy. Key findings included:

一项具有里程碑意义的随机对照试验研究（Hollis，2018）表明，在标准临床评估的同时使用QbTest可以显着更快地做出诊断决策，而不会影响准确性。主要调查结果包括：

Shorter appointments were needed to reach diagnostic decisions.

需要更短的预约才能做出诊断决定。

Clinicians were twice as likely to be able to rule out ADHD much earlier in the assessment.

临床医生在评估早期排除ADHD的可能性是对照组的两倍。

Up to 44% more patients received a diagnostic decision faster within the first six months of the evaluation compared to standard assessments alone.

与单独的标准评估相比，在评估的前六个月内，多达44%的患者更快地接受了诊断决策。

These findings are also supported by five additional studies where Qbtech technology has been shown to reduce the number of consultations needed to reach a diagnosis (NICE, Digital Technologies for Diagnostic Assessment for ADHD, 2024).

这些发现也得到了另外五项研究的支持，其中Qbtech技术已被证明可以减少达到诊断所需的咨询次数（NICE，ADHD诊断评估数字技术，2024）。

Qbtech’s objective ADHD testing technology is used by more than 12,000 clinicians across 44 states in the U.S. and routinely at a national level by organizations such as the NHS in England. The technology has been documented in more than 40 independent studies, showing benefits across the patient care pathway, including improved access to care, elevated clinician confidence, better identification of treatment effects than self-rating, and standardization of care across multiple disciplines..

Qbtech的客观ADHD测试技术在美国44个州的12000多名临床医生中使用，并且在国家层面上由英国NHS等组织常规使用。该技术已在40多项独立研究中得到证实，显示出在整个患者护理途径中的益处，包括改善获得护理的机会，提高临床医生的信心，比自我评估更好地识别治疗效果，以及跨多个学科的护理标准化。。

About Qbtech

关于Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 15 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com..

Qbtech成立于2002年，是一家瑞典私营公司，开发了领先的解决方案和产品，用于改善ADHD患者的识别，诊断，治疗和随访。Qbtech在15个国家开展业务，并在斯德哥尔摩、休斯顿和伦敦设有办事处。Qbtech是一家因其创新而备受赞誉的获奖公司，最近一次获得2022年HSJ合作奖，表彰其“与NHS的最佳心理健康合作伙伴关系”有关Qbtech的更多信息，请访问www.Qbtech.com。。